After ruling Takeda Pharmaceutical Company, Ltd. intentionally deleted evidence relevant to a trial that ended in a $9 billion verdict, a federal judge has further ruled that the drugmaker acted in bad faith in destroying evidence showing it knew about the potential health risks of its diabetes drug Actos.
U.S. District Judge Rebecca F. Doherty of the Western District of Louisiana already instructed the jury that Takeda had the duty to retain documents about Actos since 2002. The jury was free to infer the plaintiffs would have been helped by now-deleted computer data for 46 employees intimately involved in the drug’s production, the judge said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
